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Methodology
To establish validated treatment groups for effective Cisplatin
chemotherapy as well as chemoradiation dosages and to institute
negative control groups for comparison and analysis, clonogenic
assays were performed through crystal violet staining in addition to
Cell Titer Glo Luminescent Cell Viability Assays. HeLa cells were
co-cultured with diverse L. iners supernatant groups isolated from
cervical cancer patients (PT 366 and PT 370) or a BV patient (ATCC
Strain), subjected to potent doses of Cisplatin, irradiated with 1.5 Gy
or 3.0 Gy in the X-RAD, and subsequently incubated for 2 weeks.
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Figure 1. In-Vitro Cisplatin Chemotherapy Treatment Induces Apoptotic HeLa Cell Death. Results demonstrate a
negative trend in HeLa cell viability after 1.0 µg/mL of Cisplatin chemotherapy was administered. The HeLa cells illustrated a
substantial degree of sensitivity to the Cisplatin, which provides a verified standard for the L. iners supernatant experiment to
determine if they impose a potential resistant effect, enhancing HeLa cell survival.
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a sharp decline in HeLa cell survival after 1.0 µg/mL of
Cisplatin chemotherapy combined with 1.5 Gy of
radiation was distributed. This reinforces the idea of
sensitivity of cervical cancer cells to CRT interventions at
low dosages. Results clarify that the 50% pH-adjusted
NYC III Media is a validated negative control
concentration that effectively reduces HeLa cell viability
while preventing the complete elimination of all cells
present in the wells, establishing a baseline for evaluation.
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• Cervical cancer is the fourth most common cancer amongst women
worldwide and is a major cause of patient morbidity and mortality.2
• There is an insufficient amount of identified and substantiated molecular
markers to pinpoint patients who will respond poorly to treatment.
• The tumor microbiome serves as a manifestation of the potential radiosensitivity of cervical cancer cells, which further indicates how cervical
cancer cells will react to CRT interventions.
• Clarifying the damaging in-vitro effects of cancer-associated L. iners on
cervical cancer patients promotes the detection and removal of L. iners
from tumor microenvironments, leading to increased recurrence free
survival rates and improved patient outcomes.
• Knowledge of this complex and ambiguous relationship between cancerassociated L. iners and cervical cancer cells in the context of CRT
empowers the generation of enhanced prevention measures and lowrisk, focused interventions, such as probiotics, bacteriocins, and lytic
phages.
• After performing Clonogenic Assays and Cell Titer Glo Luminescent
Cell Viability Assays for HeLa cells co-cultured with 50% supernatants
produced by cancer-derived L. iners isolated from patients 366 and 370,
the HeLa cells will increase in survival after irradiation alone and after
both chemotherapy (Cisplatin) and chemoradiation treatment in
comparison to the control group of NYC III broth and the ATCC L. iners
strain treatment group. Thus, cancer-derived L. iners instigate resistance
to both radiation and chemotherapy interventions.
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Purpose & Hypothesis
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• Chemoradiotherapy (CRT) is the combined efficacious administration of
both chemotherapy (Cisplatin) and chemoradiation as an antineoplastic
and cytotoxic approach.1
• However, instances of poor clinical response to treatment,
chemoradiotherapy resistance, and incurable relapse in cervical cancer
patients are alarming, prompting the investigation of potential markers
and underlying sources of CRT resistance.
• Previous research suggests that tumor microbiomes predominated by
cancer-associated Lactobacillus iners are significantly associated with
poor patient outcomes, unfeasible recoveries, and decreased recurrence
free-survival rates.
• Cancer-associated Lactobacillus iners do not exhibit protective
capabilities in the vaginal microbiome as this species cannot maintain
intravaginal acidity, contributes to the onset and progression of infectious
conditions, and lacks the genes capable of producing hydrogen peroxide
and D-lactic acid.4
• Lactobacillus iners’ association with poor response to radiation is
potentially attributed to its distinctively adaptive, altered, heterogeneous,
and small genome size, which is notably unique in contrast to other
strains of the Lactobacillus species.3

Figure 3. Clonogenic Assay of HeLa Cell Survival Observed After Exposure to 1.5 Gy of Chemoradiation and CoCultured with Varied Supernatant Groups of 50% Concentrations Derived From Lactobacillus iners. The grouped barchart and representative image suggest a notable form of CRT resistance ascribed to the cancer-associated L. iners supernatant groups
isolated from Patient 366 and Patient 370. HeLa cells co-cultured with PT 366 L. iners demonstrated increased propagation through
its numerous sustained colonies unparalleled by other treatment groups after treated with 1.0 μg/mL of Cisplatin (the highest dose),
and the L. iners supernatant derived from PT 370 minimized the radio-sensitivity of the cervical cancer cells to the low level of
chemoradiation (1.5 Gy), suggesting that cancer-associated L. iners confer CRT resistance.
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Discussion & Conclusions

• This novel pathotype of cancer-associated Lactobacillus iners promotes the in-vitro resistance of
cervical cancer cells against CRT while modifying the local tumor immunologic
microenvironment, sustaining dysfunctional immune responses to introduced therapeutic agents
and curtailing the radio-sensitivity of cervical cancer cells.
• Thus, this proposed detrimental in-vitro influence of cancer-associated Lactobacillus iners’
supernatants on cervical cancer cells must be further scrutinized to corroborate evidence of it as a
validated marker in the tumor microbiome that signals treatment resistance and predicts poor
clinical responses to chemoradiotherapy modalities
• Discerning this association equips researchers with the insight to ameliorate recurrence-free
survival rates, overall survival rates, and the quality of life of all cervical cancer patients.
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